Organisation paid for research Program year 2025 Source: CMS Open Payments

Washington Institute for Coagulation

Neither a doctor nor a teaching hospital

Research payments

$165,268

91 payments

Through program year 2025, Washington Institute for Coagulation is reported as receiving $165,268 in research payments, across 91 payments.

By program year

4 rows
Year Kind Amount Payments
2025 Research $37,142 18
2024 Research $48,653 23
2023 Research $35,920 41
2022 Research $43,553 9

Breakdown

Who paid Research payments · program years 2022–2025
  1. CSL Behring $88,559 44 payments
  2. Pfizer Inc. $59,711 9 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $16,998 38 payments
Studies the money was for Research payments · program years 2022–2025
  1. A Phase 12 Openlabel Adaptive Doseranging Study to Assess the Safety and Tolerability of Sb525 Pf07055480 Recombinant Aav26 Human Factor 8 Gene Therapy in Adult Subjects With Severe Hemophilia A $51,969 4 payments
  2. Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral Vector Containing the Padua Variant of a Codon-optimized Human Factor IX Gene (AAV5-hFIXco-Padua, AMT-061) Administered to Adult Subjects With Severe or Moderately Severe Hemophilia B $44,599 24 payments
  3. An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects With Hemophilia B $43,960 20 payments
  4. A Phase 1/2 Open-Label, Single Ascending Dose Trial of A Self-Complementing Optimized Adeno-Associated Virus Serotype 8 Factor IX Gene Therapy (Askbio009) in Adults With Hemophilia B $16,998 38 payments
  5. An Openlabel Study in Adolescent and Adult Severe Coagulation Factor Activity 1 Hemophilia A Or B Patients With Or Without Inhibitors Comparing Standard Treatment to Pf06741086 Prophylaxis $6,084 3 payments
  6. An Openlabel Extension Study to Evaluate the Longterm Safety Tolerability and Efficacy of Marstacimab Prophylaxis in Participants With Severe Hemophilia A and B With Or Without Inhibitors $1,658 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record